PLoS ONE (Jan 2019)

OTOF mutation analysis with massively parallel DNA sequencing in 2,265 Japanese sensorineural hearing loss patients.

  • Yoh-Ichiro Iwasa,
  • Shin-Ya Nishio,
  • Akiko Sugaya,
  • Yuko Kataoka,
  • Yukihiko Kanda,
  • Mirei Taniguchi,
  • Kyoko Nagai,
  • Yasushi Naito,
  • Tetsuo Ikezono,
  • Rie Horie,
  • Yuika Sakurai,
  • Rina Matsuoka,
  • Hidehiko Takeda,
  • Satoko Abe,
  • Chiharu Kihara,
  • Takashi Ishino,
  • Shin-Ya Morita,
  • Satoshi Iwasaki,
  • Masahiro Takahashi,
  • Tsukasa Ito,
  • Yasuhiro Arai,
  • Shin-Ichi Usami

DOI
https://doi.org/10.1371/journal.pone.0215932
Journal volume & issue
Vol. 14, no. 5
p. e0215932

Abstract

Read online

The OTOF gene (Locus: DFNB9), encoding otoferlin, is reported to be one of the major causes of non-syndromic recessive sensorineural hearing loss, and is also reported to be the most common cause of non-syndromic recessive auditory neuropathy spectrum disorder (ANSD). In the present study, we performed OTOF mutation analysis using massively parallel DNA sequencing (MPS). The purpose of this study was to reveal the frequency and precise genetic and clinical background of OTOF-related hearing loss in a large hearing loss population. A total of 2,265 Japanese sensorineural hearing loss (SNHL) patients compatible with autosomal recessive inheritance (including sporadic cases) from 53 otorhinolaryngology departments nationwide participated in this study. The mutation analysis of 68 genes, including the OTOF gene, reported to cause non-syndromic hearing loss was performed using MPS. Thirty-nine out of the 2,265 patients (1.72%) carried homozygous or compound heterozygous mutations in the OTOF gene. It is assumed that the frequency of hearing loss associated with OTOF mutations is about 1.72% of autosomal recessive or sporadic SNHL cases. Hearing level information was available for 32 of 39 patients with biallelic OTOF mutations; 24 of them (75.0%) showed profound hearing loss, 7 (21.9%) showed severe hearing loss and 1 (3.1%) showed mild hearing loss. The hearing level of patients with biallelic OTOF mutations in this study was mostly severe to profound, which is consistent with the results of past reports. Eleven of the 39 patients with biallelic OTOF mutations had been diagnosed with ANSD. The genetic diagnosis of OTOF mutations has significant benefits in terms of clinical decision-making. Patients with OTOF mutations would be good candidates for cochlear implantation; therefore, the detection of OTOF mutations is quite beneficial for patients, especially for those with ANSD.